SOURCE: Rafarma Pharmaceuticals, Inc.

Rafarma Pharmaceuticals, Inc.

July 05, 2013 10:27 ET

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid

TERBUNY, RUSSIA--(Marketwired - Jul 5, 2013) - Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that in June of this year the Company entered into a production agreement to manufacture Para-Aminosalicylic Acid (PAS) to be marketed and distributed by OOO "Advance Trading," which is one of the leading distributors of PAS in Russia.

According to data provided by DSM Group (one of the leading analysts of pharmaceutical market in Russia), the PAS market in Russian Federation in 2011 was more than 8.2 Billion USD. Advance Trading is currently responsible for approximately 20% of sales of PAS in the Russian Market.

Working with Advanced Trading will allow Rafarma to increase production of PAS and to become one of the leading suppliers of this product to the Russian market.

Dave Anderson, CEO of Rafarma Pharmaceuticals, stated, "This new contract is yet another expansion of Rafarma's production capability, opening the door for more revenue."

About Rafarma Pharmaceuticals, Inc. (RAFA)

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

For more information on Rafarma Pharmaceuticals, visit: http://RAFA.QualityStocks.net

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

RELATED LINKS
www.rafarma.com
Facebook www.facebook.com/Rafarmainfo
Twitter: https://twitter.com/rafarmainfo
Video's: http://video.qualitystocks.net

Contact Information